share_log

Intuitive Surgical | 10-Q: Q3 2024 Earnings Report

Intuitive Surgical | 10-Q: Q3 2024 Earnings Report

直覺外科公司 | 10-Q：2024財年三季報
美股SEC公告 ·  2024/10/18 16:49

Moomoo AI 已提取核心訊息

Intuitive Surgical reported robust Q3 2024 financial results, with total revenue increasing 17% to $2.04 billion. Instruments and accessories revenue grew 18% to $1.26 billion, driven by an 18% rise in da Vinci procedures to 670,000 and a 73% increase in Ion procedures to 25,000. Systems revenue rose 17% to $445 million as the company placed 379 da Vinci systems, including 110 next-generation da Vinci 5 systems.Operating income increased 24% to $577 million, with a gross profit margin of 67.4%. The company maintained strong profitability despite higher costs associated with the da Vinci 5 surgical system launch. The installed base grew 15% year-over-year to approximately 9,539 da Vinci systems globally, while the Ion system installed base expanded 50% to 736 systems.Geographic expansion continued with strong procedure growth in Japan, Germany, UK, India, France, and Italy. The company ended the quarter with $8.31 billion in cash and investments, up $0.97 billion from year-end 2023. Looking ahead, Intuitive expects continued investments in product development and manufacturing capacity expansion, with planned capital expenditures of $1-1.2 billion in 2024.
Intuitive Surgical reported robust Q3 2024 financial results, with total revenue increasing 17% to $2.04 billion. Instruments and accessories revenue grew 18% to $1.26 billion, driven by an 18% rise in da Vinci procedures to 670,000 and a 73% increase in Ion procedures to 25,000. Systems revenue rose 17% to $445 million as the company placed 379 da Vinci systems, including 110 next-generation da Vinci 5 systems.Operating income increased 24% to $577 million, with a gross profit margin of 67.4%. The company maintained strong profitability despite higher costs associated with the da Vinci 5 surgical system launch. The installed base grew 15% year-over-year to approximately 9,539 da Vinci systems globally, while the Ion system installed base expanded 50% to 736 systems.Geographic expansion continued with strong procedure growth in Japan, Germany, UK, India, France, and Italy. The company ended the quarter with $8.31 billion in cash and investments, up $0.97 billion from year-end 2023. Looking ahead, Intuitive expects continued investments in product development and manufacturing capacity expansion, with planned capital expenditures of $1-1.2 billion in 2024.
直覺外科公司報告了2024年第三季度強勁的財務業績，總營業收入增長了17%，達到了20.4億美金。儀器和配件的營業收入增長了18%，達到了12.6億美金，這得益於達芬奇手術數量增長了18%，達到670,000次，而離子手術數量增長了73%，達到了25,000次。系統營業收入上漲了17%，達到44500萬美金，公司交付了379臺達芬奇系統，其中包括110臺下一代達芬奇5系統。營業收入增長了24%，達到57700萬美金，毛利潤率爲67.4%。儘管與達芬奇5外科系統的發佈相關的成本增加，公司仍維持了強勁的盈利能力。全球已安裝的達芬奇系統基數同比增長了15%，約爲9,539台，而離子系統的已安裝基數擴...展開全部
直覺外科公司報告了2024年第三季度強勁的財務業績，總營業收入增長了17%，達到了20.4億美金。儀器和配件的營業收入增長了18%，達到了12.6億美金，這得益於達芬奇手術數量增長了18%，達到670,000次，而離子手術數量增長了73%，達到了25,000次。系統營業收入上漲了17%，達到44500萬美金，公司交付了379臺達芬奇系統，其中包括110臺下一代達芬奇5系統。營業收入增長了24%，達到57700萬美金，毛利潤率爲67.4%。儘管與達芬奇5外科系統的發佈相關的成本增加，公司仍維持了強勁的盈利能力。全球已安裝的達芬奇系統基數同比增長了15%，約爲9,539台，而離子系統的已安裝基數擴展了50%，達到了736台。地理擴張持續進行，在日本、德國、英國、印度、法國和意大利的手術數量增長顯著。公司在季度末的現金和投資總額爲83.1億美金，比2023年年末增加了9.7億美金。展望未來，直覺外科公司預計將繼續投資於產品開發和製造能力的擴展，計劃在2024年進行10-12億美金的資本支出。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Anbio Biotechnology
    NNNN
    -- 6.740
    Repligen
    RGEN
    -- 144.470
    Akoya Biosciences
    AKYA
    -- 1.620
    Retractable Technologies
    RVP
    -- 0.752
    Daxor
    DXR
    -- 8.100
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    美聯儲暫停降息，你如何調整持倉？
    美聯儲宣布基準利率維持在4.25%—4.50%不變，符合市場預期。你會如何配置資產？ 展开
    FOMC新聞發佈會，2025年1月29日